You are here
This document guides costing practitioners on the steps to capturing end-to-end COVID-19 activity and expenses under the National Partnership Agreement (NPA). It identifies the principles to be applied, the scope of activity and costs to be funded, cost allocation methods and NPA specific cost centres for cost allocation. This document also introduces two new non-patient products and provides information on how to create and map intermediate products.
On 13 March 2020, the Commonwealth and all state and territory governments signed the National Partnership on COVID-19 Response, in order to provide financial assistance for the additional costs incurred by health services in responding to the coronavirus disease 2019 (COVID-19) outbreak.
IHPA has developed a robust set of standard costs for the revised List of standard items associated with conducting clinical trials in Australia.
*The documents on this page may not meet accessibility (WCAG 2.0) requirements. If you need help please contact us using the enquiries.ihpa [at] ihpa.gov.au (IHPA enquiries).